GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Formycon AG (LTS:0W4N) » Definitions » Accounts Receivable

Formycon AG (LTS:0W4N) Accounts Receivable : €23.69 Mil (As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Formycon AG Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Formycon AG's accounts receivables for the quarter that ended in Dec. 2024 was €23.69 Mil.

Accounts receivable can be measured by Days Sales Outstanding. Formycon AG's Days Sales Outstanding for the quarter that ended in Dec. 2024 was 101.07.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Formycon AG's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was €-14.16.


Formycon AG Accounts Receivable Historical Data

The historical data trend for Formycon AG's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Formycon AG Accounts Receivable Chart

Formycon AG Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.89 10.91 14.31 11.61 23.69

Formycon AG Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.31 30.97 11.61 10.55 23.69

Formycon AG Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Formycon AG Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Formycon AG's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=23.693/42.781*91
=101.07

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Formycon AG's accounts receivable are only considered to be worth 75% of book value:

Formycon AG's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(41.84+0.75 * 23.693+0.5 * 0.262-309.872
-0-0)/17.664
=-14.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Formycon AG Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Formycon AG's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Formycon AG Business Description

Traded in Other Exchanges
Address
Fraunhoferstrasse 15, Martinsried, Planegg, BY, DEU, 82152
Formycon AG is a globally operating, independent biosimilars specialist with a comprehensive product pipeline and a scalable platform for developing biosimilar drugs for various indications, including ophthalmology, immunology, and immunobiology. Its product, FYB201 (ranibizumab), is an approved biosimilar product for Lucentis, is on the market in the United States and Canada, Europe, the Middle East and North Africa (MENA), and other geographical regions. The other product candidates in its pipeline include FYB202, FYB203, FYB206, FYB207, FYB208, FYB209, and FYB210, which are biosimilar projects being developed for the treatment of various indications. Geographically, the company generates maximum revenue from Switzerland, followed by Germany.

Formycon AG Headlines

No Headlines